SI-BONE, Inc. (NASDAQ:SIBN) Shares Acquired by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY increased its position in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 5.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,386,031 shares of the company’s stock after buying an additional 69,831 shares during the period. Paradigm Capital Management Inc. NY owned about 3.30% of SI-BONE worth $19,432,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Virtus Fund Advisers LLC purchased a new stake in shares of SI-BONE during the fourth quarter worth about $40,000. Mainstream Capital Management LLC acquired a new position in shares of SI-BONE in the 4th quarter valued at approximately $53,000. R Squared Ltd purchased a new position in shares of SI-BONE during the 4th quarter valued at approximately $73,000. KLP Kapitalforvaltning AS bought a new stake in shares of SI-BONE in the fourth quarter worth $97,000. Finally, Proficio Capital Partners LLC acquired a new position in SI-BONE during the 4th quarter worth $155,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

SI-BONE Trading Down 1.7%

Shares of NASDAQ:SIBN opened at $19.45 on Tuesday. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The company’s 50-day moving average price is $14.92 and its 200 day moving average price is $15.08. The company has a market cap of $828.86 million, a PE ratio of -21.14 and a beta of 0.82. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $20.05.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.09. The business had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. Sell-side analysts anticipate that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and issued a $24.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Truist Financial lifted their target price on SI-BONE from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th.

Insider Activity at SI-BONE

In other news, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the transaction, the senior vice president now directly owns 244,878 shares in the company, valued at $3,462,574.92. This trade represents a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Anshul Maheshwari sold 4,937 shares of the business’s stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $19.02, for a total value of $93,901.74. Following the sale, the chief financial officer now directly owns 232,069 shares in the company, valued at approximately $4,413,952.38. The trade was a 2.08% decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,153 shares of company stock worth $935,040 in the last 90 days. Corporate insiders own 4.00% of the company’s stock.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.